main inclusion criteria: first onset of covid-19 symptoms \<7 days at randomization, symptoms such as fever and/or chills, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. have a positive sars-cov-2 reverse transcription-polymerase chain reaction (rt-pcr) test using an appropriate sample such as nasopharyngeal (np), nasal, oropharyngeal, or saliva within 72 hours prior to randomization. a historical record of a positive result from a test conducted ≤72 hours prior to randomization is acceptable. male or female patients ≥18 years of age at the time of signing informed consent. agree to use an adequate method of contraception throughout the study period and for 6 months after the dose of study drug is administered. women of childbearing potential (wocbp) must have a negative urinary pregnancy test at screening. main

main inclusion criteria: first onset of covid-19 symptoms \<7 days at randomization, symptoms such as fever and/or chills, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. have a positive sars-cov-2 reverse transcription-polymerase chain reaction (rt-pcr) test using an appropriate sample such as nasopharyngeal (np), nasal, oropharyngeal, or saliva within 72 hours prior to randomization. a historical record of a positive result from a test conducted ≤72 hours prior to randomization is acceptable. male or female patients ≥18 years of age at the time of signing informed consent. agree to use an adequate method of contraception throughout the study period and for 6 months after the dose of study drug is administered. women of childbearing potential (wocbp) must have a negative urinary pregnancy test at screening. main

main inclusion criteria: first onset of covid-19 symptoms <7 days at randomization, symptoms such as fever and/or chills, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. have a positive sars-cov-2 reverse transcription-polymerase chain reaction (rt-pcr) test using an appropriate sample such as nasopharyngeal (np), nasal, oropharyngeal, or saliva within 72 hours prior to randomization. a historical record of a positive result from a test conducted ≤72 hours prior to randomization is acceptable. male or female patients ≥18 years of age at the time of signing informed consent. agree to use an adequate method of contraception throughout the study period and for 6 months after the dose of study drug is administered. women of childbearing potential (wocbp) must have a negative urinary pregnancy test at screening. main

main inclusion criteria: first onset of covid-19 symptoms <7 days at randomization, symptoms such as fever and/or chills, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. have a positive sars-cov-2 reverse transcription-polymerase chain reaction (rt-pcr) test using an appropriate sample such as nasopharyngeal (np), nasal, oropharyngeal, or saliva within 72 hours prior to randomization. a historical record of a positive result from a test conducted ≤72 hours prior to randomization is acceptable. male or female patients ≥18 years of age at the time of signing informed consent. agree to use an adequate method of contraception throughout the study period and for 6 months after the dose of study drug is administered. women of childbearing potential (wocbp) must have a negative urinary pregnancy test at screening. main